| Detection of renal cell carcinoma using plasma and urine cell-free DNA methylomes PV Nuzzo, JE Berchuck, K Korthauer, S Spisak, AH Nassar, S Abou Alaiwi, ... Nature medicine 26 (7), 1041-1043, 2020 | 188 | 2020 |
| Distribution of KRASG12C Somatic Mutations across Race, Sex, and Cancer Type AH Nassar, E Adib, DJ Kwiatkowski New England Journal of Medicine 384 (2), 185-187, 2021 | 101 | 2021 |
| Clonal hematopoiesis is associated with adverse outcomes in multiple myeloma patients undergoing transplant TH Mouhieddine, AS Sperling, R Redd, J Park, M Leventhal, CJ Gibson, ... Nature communications 11 (1), 2996, 2020 | 96 | 2020 |
| Mutational analysis of 472 urothelial carcinoma across grades and anatomic sites AH Nassar, R Umeton, J Kim, K Lundgren, L Harshman, EM Van Allen, ... Clinical Cancer Research 25 (8), 2458-2470, 2019 | 95 | 2019 |
| Integrative molecular characterization of sarcomatoid and rhabdoid renal cell carcinoma Z Bakouny, DA Braun, SA Shukla, W Pan, X Gao, Y Hou, A Flaifel, S Tang, ... Nature communications 12 (1), 808, 2021 | 88* | 2021 |
| Safety and efficacy of restarting immune checkpoint inhibitors after clinically significant immune-related adverse events in metastatic renal cell carcinoma S Abou Alaiwi, W Xie, AH Nassar, S Dudani, D Martini, Z Bakouny, ... Journal for Immunotherapy of Cancer 8 (1), 2020 | 64 | 2020 |
| A model combining clinical and genomic factors to predict response to PD-1/PD-L1 blockade in advanced urothelial carcinoma AH Nassar, KW Mouw, O Jegede, AB Shinagare, J Kim, CJ Liu, ... British journal of cancer 122 (4), 555-563, 2020 | 62 | 2020 |
| Mammalian SWI/SNF complex genomic alterations and immune checkpoint blockade in solid tumors S Abou Alaiwi, AH Nassar, W Xie, Z Bakouny, JE Berchuck, DA Braun, ... Cancer immunology research 8 (8), 1075-1084, 2020 | 59* | 2020 |
| Clinical outcomes and toxic effects of single-agent immune checkpoint inhibitors among patients aged 80 years or older with cancer: a multicenter international cohort study CA Nebhan, A Cortellini, W Ma, T Ganta, H Song, F Ye, R Irlmeier, ... JAMA oncology 7 (12), 1856-1861, 2021 | 58 | 2021 |
| Reprogramming of the FOXA1 cistrome in treatment-emergent neuroendocrine prostate cancer SC Baca, DY Takeda, JH Seo, J Hwang, SY Ku, R Arafeh, T Arnoff, ... Nature communications 12 (1), 1979, 2021 | 57 | 2021 |
| PD-L1 expression and clinical outcomes to cabozantinib, everolimus, and sunitinib in patients with metastatic renal cell carcinoma: analysis of the randomized clinical trials … A Flaifel, W Xie, DA Braun, M Ficial, Z Bakouny, AH Nassar, RB Jennings, ... Clinical Cancer Research 25 (20), 6080-6088, 2019 | 50 | 2019 |
| Prevalence of pathogenic germline cancer risk variants in high-risk urothelial carcinoma AH Nassar, S Abou Alaiwi, SH AlDubayan, N Moore, KW Mouw, ... Genetics in Medicine 22 (4), 709-718, 2020 | 48 | 2020 |
| CDKN2A Alterations and Response to Immunotherapy in Solid Tumors E Adib, AH Nassar, EW Akl, S Abou Alaiwi, PV Nuzzo, TH Mouhieddine, ... Clinical Cancer Research 27 (14), 4025-4035, 2021 | 46* | 2021 |
| Activity of cabozantinib after immune checkpoint blockade in metastatic clear-cell renal cell carcinoma BA McGregor, AKA Lalani, W Xie, JA Steinharter, ZE Bakouny, DJ Martini, ... European Journal of Cancer 135, 203-210, 2020 | 45 | 2020 |
| Plasma cell-free DNA variant analysis compared with methylated DNA analysis in renal cell carcinoma K Lasseter, AH Nassar, L Hamieh, JE Berchuck, PV Nuzzo, K Korthauer, ... Genetics in Medicine 22 (8), 1366-1373, 2020 | 44 | 2020 |
| Ancestry-driven recalibration of tumor mutational burden and disparate clinical outcomes in response to immune checkpoint inhibitors AH Nassar, E Adib, S Abou Alaiwi, T El Zarif, S Groha, EW Akl, PV Nuzzo, ... Cancer Cell 40 (10), 1161-1172. e5, 2022 | 37 | 2022 |
| Germline variants associated with toxicity to immune checkpoint blockade S Groha, SA Alaiwi, W Xu, V Naranbhai, AH Nassar, Z Bakouny, T El Zarif, ... Nature medicine 28 (12), 2584-2591, 2022 | 26 | 2022 |
| Variation in targetable genomic alterations in non-small cell lung cancer by genetic ancestry, sex, smoking history, and histology E Adib, AH Nassar, S Abou Alaiwi, S Groha, EW Akl, LM Sholl, ... Genome Medicine 14 (1), 39, 2022 | 26 | 2022 |
| CDH1 germline variants are enriched in patients with colorectal cancer, gastric cancer, and breast cancer E Adib, T El Zarif, AH Nassar, EW Akl, S Abou Alaiwi, TH Mouhieddine, ... British journal of cancer 126 (5), 797-803, 2022 | 20 | 2022 |
| Tumors with TSC mutations are sensitive to CDK7 inhibition through NRF2 and glutathione depletion M Zarei, H Du, AH Nassar, RE Yan, K Giannikou, SH Johnson, HC Lam, ... Journal of Experimental Medicine 216 (11), 2635-2652, 2019 | 17 | 2019 |
Toni ChoueiriDana-Farber Cancer Institute在 dfci.harvard.edu 的电子邮件经过验证
